A new component is being added to the state’s rare disease treatment program – a wide range of services will be available for patients with spinal muscular atrophy, Duchenne, and Becker muscular dystrophy. It is all about ambulatory, inpatient, and research services.
The Minister of Health, Mikheil Sarveladze, together with Deputy Tea Giorgadze, met with the heads of clinics that can join the program and offer all services to beneficiaries. The parties discussed the importance of these services and discussed their effectiveness for patient health.
The Ministry of Internally Displaced Persons, Labor, Health, and Social Welfare of Georgia shared the glimpses of the meeting on its official Facebook Page on April 22, 2026, Wednesday. The Georgian Health Ministry also shared a small note about the meeting along with its glimpses.
As Mikheil Sarjveladze noted, it is important for the organization to take care of each patient and protect their right to health. According to the Minister, one of the most important components of neuromuscular diseases treatment is monitoring their progress, and by implementing the news, beneficiaries will be able to access a wide range of services they need.
During the program, the beneficiaries will benefit from consultation with neurologist, cardiologist, pulmonologist, endocrinologist, gastroenterologist/nutritionist, orthopedic, as well as clinical-laboratory and instrumental studies such as: electrocardiography, echocardioscopy, 24-hour holter monitoring, spirometry, densitometry, vitamin D concentration determination, chest x-ray, spine X-ray, general blood analysis, general urine analysis, determining creatinkinase, kidney functional samples (urine, creatinine), liver functional samples (Tute phosphatase, alt, ast), electrolytes (sodium, potassium, chlorine, magnesium, iron) detection, blood glucose detection, research on hidden bleeding.
The services will be financed by the state and the services for patients will be completely free.
At the same time, work continues to ensure that adult beneficiaries will receive research, inpatient, and outpatient services along with children, in the new component of the state treatment program for rare diseases.
